Protagenic Therapeutics, Inc.\new Increase (Decrease) in Accrued Liabilities
Protagenic Therapeutics, Inc.\new (PTIX) reported Increase (Decrease) in Accrued Liabilities of -$9.04 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$9.04K, a 103.52% decline year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $13.54K, a 82.74% decline year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$155.03K, a 1206.95% decline year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$97.85K, a 286.12% decline year-over-year.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for fiscal 2026 was $17.42K, a 91.54% decline from fiscal 2025.
- Protagenic Therapeutics, Inc.\new increase (decrease) in accrued liabilities for fiscal 2025 was $206.04K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.04K 10-Q · filed 2026-08-19 | $4.50K derived: sum of 2 quarters · filed 2026-08-19 | -$150.53K derived: sum of 3 quarters · filed 2026-08-19 | -$248.38K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $13.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | -$141.49K derived: sum of 2 quarters · filed 2026-08-14 | -$239.34K derived: sum of 3 quarters · filed 2026-08-14 | $17.42K 10-K · filed 2026-08-14 |
| 2025-12-31 | -$155.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | -$252.87K derived: sum of 2 quarters · filed 2026-03-09 | $3.88K 10-Q · filed 2026-03-09 | $82.31K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | -$97.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-26 | $158.91K 10-Q · filed 2025-11-26 | $237.34K derived: sum of 3 quarters · filed 2026-08-19 | $251.35K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $256.76K 10-Q · filed 2026-08-19 | $335.19K derived: sum of 2 quarters · filed 2026-08-19 | $349.19K derived: sum of 3 quarters · filed 2026-08-19 | $401.76K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $78.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $92.44K derived: sum of 2 quarters · filed 2026-08-14 | $145.01K derived: sum of 3 quarters · filed 2026-08-14 | $206.04K 10-K · filed 2026-08-14 |
| 2024-12-31 | $14.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $66.58K derived: sum of 2 quarters · filed 2026-03-09 | $127.61K 10-Q · filed 2026-03-09 | |
| 2024-09-30 | $52.57K derived: 10-Q 6 month − 10-QT 3 month · filed 2025-11-26 | $113.60K 10-Q · filed 2025-11-26 | ||
| 2024-06-30 | $61.03K 10-QT · filed 2025-09-10 | |||
| 2011-09-30 | $1.76M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $2.31M 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $549.00K 10-Q/A · filed 2011-09-07 | |||
| 2010-09-30 | -$2.42M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | -$5.31M 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | -$2.89M 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |